These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 27723556)

  • 1. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA.
    Morishita M; Takahashi Y; Matsumoto A; Nishikawa M; Takakura Y
    Biomaterials; 2016 Dec; 111():55-65. PubMed ID: 27723556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Class I Tumor Antigen Presentation via Cytosolic Delivery of Exosomal Cargos by Tumor-Cell-Derived Exosomes Displaying a pH-Sensitive Fusogenic Peptide.
    Morishita M; Takahashi Y; Nishikawa M; Ariizumi R; Takakura Y
    Mol Pharm; 2017 Nov; 14(11):4079-4086. PubMed ID: 28977747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice.
    Morishita M; Takahashi Y; Nishikawa M; Sano K; Kato K; Yamashita T; Imai T; Saji H; Takakura Y
    J Pharm Sci; 2015 Feb; 104(2):705-13. PubMed ID: 25393546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice.
    Yildirim M; Yildirim TC; Turay N; Bildik T; Ibibik B; Evcili I; Ersan PG; Tokat UM; Sahin O; Gursel I
    Immunol Lett; 2021 Nov; 239():32-41. PubMed ID: 34418488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation.
    Di Bonito P; Chiozzini C; Arenaccio C; Anticoli S; Manfredi F; Olivetta E; Ferrantelli F; Falcone E; Ruggieri A; Federico M
    Int J Nanomedicine; 2017; 12():4579-4591. PubMed ID: 28694699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model.
    Shamili FH; Bayegi HR; Salmasi Z; Sadri K; Mahmoudi M; Kalantari M; Ramezani M; Abnous K
    Int J Pharm; 2018 Oct; 549(1-2):218-229. PubMed ID: 30075248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined encapsulation of a tumor antigen and immune cells using a self-assembling immunostimulatory DNA hydrogel to enhance antigen-specific tumor immunity.
    Umeki Y; Saito M; Kusamori K; Tsujimura M; Nishimura M; Takahashi Y; Takakura Y; Nishikawa M
    J Control Release; 2018 Oct; 288():189-198. PubMed ID: 30219278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
    Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
    Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple and powerful co-delivery system based on pH-responsive metal-organic frameworks for enhanced cancer immunotherapy.
    Duan F; Feng X; Yang X; Sun W; Jin Y; Liu H; Ge K; Li Z; Zhang J
    Biomaterials; 2017 Apr; 122():23-33. PubMed ID: 28107662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
    Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
    Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
    Li H; Li Y; Wang X; Hou Y; Hong X; Gong T; Zhang Z; Sun X
    Theranostics; 2017; 7(18):4383-4398. PubMed ID: 29158834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes derived from tumor cells genetically modified to express Mycobacterium tuberculosis antigen: a novel vaccine for cancer therapy.
    Koyama Y; Ito T; Hasegawa A; Eriguchi M; Inaba T; Ushigusa T; Sugiura K
    Biotechnol Lett; 2016 Nov; 38(11):1857-1866. PubMed ID: 27484689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models.
    Cho JA; Lee YS; Kim SH; Ko JK; Kim CW
    Cancer Lett; 2009 Mar; 275(2):256-65. PubMed ID: 19036499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
    Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Front Immunol; 2018; 9():824. PubMed ID: 29740437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of exosomes carrying TSA derived from HLA-A2-positive human white buffy coat and polyI:C for use as a subcellular antitumor vaccination.
    Ren WN; Chang CK; Fan HH; Guo F; Ren YN; Yang J; Guo J; Li X
    J Immunoassay Immunochem; 2011; 32(3):207-18. PubMed ID: 21574092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.